This work is licensed under a Table 1.
Participant characteristics at first visit. Data are presented as n (%), median (IQR) (22).
| Control group (n = 52) | AI group (n = 52) | P-value | |
|---|---|---|---|
| Age (years) | 63.5 (58.8; 69.0) | 64.5 (58.8; 71.0) | 0.91 |
| Ethnicity | 0.90 | ||
| Anglo-Saxon | 33 (63.5) | 33 (63.5) | |
| European | 16 (30.8) | 14 (26.9) | |
| Asian | 3 (5.8) | 4 (7.7) | |
| Other | 0 (0) | 1 (1.9) | |
| BMI (kg/m2) | 28.6 (26.0; 33.0) | 28.6 (25.6; 34.1) | 0.73 |
| Breast pathology | <0.001 | ||
| Early breast cancer | 17 (32.7) | 43 (82.7) | |
| Locally advanced breast cancer | 0 (0) | 9 (17.3) | |
| DCIS | 23 (44.2) | 0 (0) | |
| Other breast pathologya | 12 (23.1) | 0 (0) | |
| Breast treatment | |||
| Aromatase inhibitor | 0 (0) | 52 (100) | <0.001 |
| Anastrozole | 0 (0) | 26 (50) | |
| Letrozole | 0 (0) | 26 (50) | |
| Surgery | 46 (88.5) | 52 (100) | 0.03 |
| Radiotherapy | 22 (42.3) | 43 (82.7) | <0.001 |
| Chemotherapy | 0 (0) | 15 (28.8) | <0.001 |
| Trastuzumab | 0 (0) | 6 (11.5) | 0.03 |
| Smoking status | 0.28 | ||
| Never | 22 (42.3) | 29 (55.8) | |
| Current | 5 (9.6) | 6 (11.5) | |
| Ex-smoker | 25 (48.1) | 17 (32.7) | |
| Alcohol intake (STD/day) | 0.65 | ||
| No intake | 28 (53.8) | 23 (44.2) | |
| <1 | 16 (30.8) | 22 (42.3) | |
| 1–2 | 6 (11.5) | 5 (9.6) | |
| >2 | 2 (3.9) | 2 (3.9) | |
| Activity level (steps/day) | 5790 (4030; 7117) | 4949 (3197; 8240) | 0.92 |
| ASCVD riskb | 0.49 | ||
| Low | 17 (34.0) | 18 (35.3) | |
| Borderline | 7 (14.0) | 4 (7.8) | |
| Intermediate | 12 (24.0) | 18 (35.3) | |
| High | 14 (28.0) | 11 (21.6) | |
| CVD risk factors | |||
| Metabolic syndromec | 15 (28.8) | 17 (32.7) | 0.83 |
| CVD | 2 (3.9) | 2. (3.9) | 1.00 |
| Cerebrovascular disease | 5 (9.6) | 2 (3.9) | 0.44 |
| Pre-diabetes or diabetes | 3 (5.8) | 2 (3.9) | 1.00 |
| Hypertension | 17 (32.7) | 23 (44.2) | 0.31 |
| Hypercholesterolaemia | 17 (32.7) | 13 (25.0) | 0.52 |
| Family history of premature CVD | 8 (15.4) | 9 (17.6) | 0.97 |
| Family history of premature cerebrovascular disease | 3 (5.8) | 3 (5.9) | 1.00 |
| Premature menopause | 5 (9.6) | 6 (11.5) | 1.00 |
| CVD medications | |||
| Antiplatelet | 4 (7.7) | 4 (7.7) | 1.00 |
| Anticoagulation | 2 (3.9) | 3 (5.8) | 1.00 |
| Antihypertensive | 17 (32.7) | 23 (44.2) | 0.31 |
| Lipid lowering | 9 (17.3) | 8 (15.4) | 1.00 |
| Glucose lowering | 0 (0) | 0 (0) | 1.00 |
| AAC score | 0.75 | ||
| 0–1 | 33 (75.0) | 30 (78.9) | |
| 2–3 | 5 (11.4) | 5 (13.2) | |
| >3 | 6 (13.6) | 3 (7.9) |
aOther breast pathology included atypical ductal hyperplasia, fibrous tissue, lobular carcinoma in situ, microcalcifications and papilloma.
bThe diagnosis of metabolic syndrome was made based on the USA National Cholesterol Education Program's Adult Treatment Panel III criteria, as revised by the American Heart Association (48).
c ASCVD risk level was assessed using the American College of Cardiology ASCVD Risk Estimator Plus Calculator (49) (individuals with pre-existing CVD or cerebrovascular disease were automatically categorised as high risk).
AAC, abdominal aortic calcification; AI, aromatase inhibitor; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CVD, cardiovascular disease; DCIS, ductal carcinoma insitu; LCIS, luminal carcinoma insitu; STD, standard drinks.